TL;DR
Researchers have developed a novel "CTCR model" using circulating tumor cell (CTC)-related genes to predict prognosis in lung adenocarcinoma (LUAD). This model outperforms traditional clinical markers and reveals insights into how tumor immunity influences patient outcomes, identifying RAB26 as a key gene promoting LUAD proliferation.
What Problem Does This Paper Address?
Lung adenocarcinoma (LUAD) is a leading cause of cancer-related deaths, largely due to its tendency to invade and metastasize. Circulating tumor cells (CTCs) are known precursors of metastasis and are thought to possess cancer stem cell (CSC) characteristics. However, understanding the specific genetic factors related to CTCs that drive LUAD progression and impact patient prognosis has been challenging. This paper aims to address this by developing a predictive model based on CTC-related genes to better stratify patients and understand the underlying biological mechanisms, particularly concerning tumor immunity.
Methods
The study employed a multi-stage approach:
- Data Acquisition and Cohort Building: RNA-sequencing and clinical data from LUAD patients were obtained from the TCGA database (training cohort, n=447) and GEO database (validation cohorts, GSE72094, n=328; GSE42127, n=132).
- Identification of CTC-Related Genes: Differentially expressed genes (DEGs) associated with CTCs, primary tumors, and metastatic lesions were identified using data from the GSE58355 dataset. A Venn diagram was used to pinpoint overlapping genes.
- Prognostic Model Construction: A LASSO penalty-Cox regression analysis was performed on the identified DEGs to select a minimal set of genes for a prognostic risk model. This resulted in the "CTCR model."
- Model Validation: The CTCR model's predictive ability was validated in independent cohorts using Kaplan-Meier (KM) survival curves and time-dependent Receiver Operating Characteristic (ROC) curve analysis.
- Functional Enrichment and Immune Analysis: DEGs between high- and low-risk groups were analyzed using Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses to identify enriched biological processes and signaling pathways, particularly those related to immunity. The ESTIMATE algorithm was used to assess the tumor microenvironment.
- Experimental Validation: Western blot, CCK-8 (cell proliferation), and colony formation assays were conducted to validate the biological function of a key identified gene, RAB26, in LUAD cell lines.
Datasets
- Training Cohort: TCGA database (n=447)
- Validation Cohorts:
- GEO database: GSE72094 (n=328)
- GEO database: GSE42127 (n=132)
- Gene Expression Data for DEG Identification: GSE58355 dataset.
- Normal Tissue Data: GTEx database (n=347)
No new benchmarks were introduced; the study utilized existing public datasets.
Key Insights and Ideas
- CTCs as a Prognostic Indicator: The study reinforces the idea that CTCs are not just markers of metastasis but contain genetic information that can predict patient outcomes.
- The Power of Gene Signatures: By identifying a small panel of CTC-related genes, a robust prognostic model can be built, potentially simplifying risk assessment compared to complex genomic profiling.
- Immune Microenvironment's Role: The research highlights a strong link between the identified DEGs and immune-related pathways, suggesting that the tumor's immune landscape is intrinsically tied to the risk score derived from CTC-related genes.
- RAB26 as a Pro-Tumorigenic Factor: The experimental validation of RAB26's role in promoting LUAD cell proliferation and its association with immune cell infiltration points to it as a potential therapeutic target.
Key Results
- CTCR Model Construction: A 4-gene risk model (RAB26, EPYC, MMP7, and FOS) was constructed, named the CTCR model.
- Prognostic Performance: The CTCR model successfully divided patients into high- and low-risk groups, with the high-risk group exhibiting significantly worse overall survival (OS).
- Superiority over Clinical Markers: ROC analysis showed the CTCR model outperformed traditional clinical markers (age, sex, stage, smoking history) in predicting LUAD prognosis. For instance, in the TCGA cohort, the risk score achieved an AUC of 0.699 for 1-year survival, compared to 0.525 for pathological stage.
- Immune Correlation: DEGs between risk groups were significantly enriched in immune-related pathways (e.g., humoral immune response, cell chemotaxis, IL-17 signaling). The low-risk group had a higher immune score.
- RAB26 Function: Overexpression of RAB26 promoted LUAD cell proliferation, while knockdown inhibited it. RAB26 expression was also correlated with immune cell infiltration, particularly negatively with NK cells.
Limitations and Future Work
- Public Database Reliance: The study acknowledges that using public databases for data acquisition and validation, while common, might have inherent limitations. Further prospective clinical validation is recommended.
- Mechanism of RAB26: While RAB26's role in proliferation and immune infiltration is shown, the specific molecular mechanisms and pathways through which it affects the tumor microenvironment and promotes LUAD require further in-depth investigation.
- Immune Checkpoint Inhibitor Therapy: The study noted that patients with low risk scores might benefit from immune checkpoint inhibitor (ICI) therapy due to higher expression of certain immune checkpoints. This suggests a potential avenue for personalized treatment strategies, which warrants further exploration.
- Broader Validation: While two validation cohorts were used, the authors suggest that further investigation is needed to validate the CTCR model's robustness across diverse patient populations.
Summary updated